Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer

NCT00387465 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

94

Enrollment

NIH

Sponsor class

Conditions

Recurrent Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer

Interventions

DRUG: Azacitidine 30mg/m2
DRUG: Entinostat
DRUG: Azacitidine 40mg/m2

Sponsor

National Cancer Institute (NCI)